Li Dai, Xia Ke, Li Nian-Sheng, Luo Dan, Wang Shan, Jiang De-Jian, Deng Han-Wu, Li Yuan-Jian
Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, No. 110 Xiang-Ya Road, Changsha 410078, China.
Can J Physiol Pharmacol. 2007 Aug;85(8):783-9. doi: 10.1139/y07-073.
Previous studies have indicated that nitric oxide synthase (NOS) inhibitors can induce an increase of blood pressure and exacerbate myocardial injury induced by ischemia and reperfusion, whereas angiotensin II receptor antagonists protect the myocardium against injury induced by ischemia and reperfusion. Isolated hearts from male spontaneously hypertensive rats (SHR) or male Wistar-Kyoto rats (WKY) were subjected to 20 min global ischemia and 30 min reperfusion. Heart rate, coronary flow, left ventricular pressure, and its first derivatives (+/-dP/dt(max)) were recorded, and serum concentrations of asymmetric dimethylarginine (ADMA) and NO and the release of creatine kinase in coronary effluent were measured. The level of ADMA was significantly increased and the concentration of NO was decreased in SHR. Ischemia and reperfusion significantly inhibited the recovery of cardiac function and increased the release of creatine kinase, and ischemia and reperfusion-induced myocardial injury in SHR was aggravated compared with WKY. Vasodilation responses to acetylcholine of aortic rings were decreased in SHR. Treatment with losartan (30 mg/kg) for 14 days significantly lowered blood pressure, elevated the plasma level of NO, and decreased the plasma concentration of ADMA in SHR. Treatment with losartan significantly improved endothelium-dependent relaxation and cardiac function during ischemia and reperfusion in SHR. Exogenous ADMA also aggravated myocardial injury induced by ischemia and reperfusion in isolated perfused heart of WKY, as shown by increasing creatine kinase release and decreasing cardiac function. The present results suggest that the protective effect of losartan on myocardial injury induced by ischemia and reperfusion is related to the reduction of ADMA levels.
先前的研究表明,一氧化氮合酶(NOS)抑制剂可导致血压升高,并加重缺血再灌注诱导的心肌损伤,而血管紧张素II受体拮抗剂可保护心肌免受缺血再灌注诱导的损伤。将雄性自发性高血压大鼠(SHR)或雄性Wistar-Kyoto大鼠(WKY)的离体心脏进行20分钟全心缺血和30分钟再灌注。记录心率、冠脉流量、左心室压力及其一阶导数(+/-dP/dt(max)),并测定血清不对称二甲基精氨酸(ADMA)和NO浓度以及冠脉流出液中肌酸激酶的释放量。SHR中ADMA水平显著升高,NO浓度降低。缺血再灌注显著抑制心脏功能的恢复并增加肌酸激酶的释放,与WKY相比,SHR中缺血再灌注诱导的心肌损伤加重。SHR中主动脉环对乙酰胆碱的舒张反应降低。用氯沙坦(30 mg/kg)治疗14天可显著降低SHR的血压,提高血浆NO水平,并降低血浆ADMA浓度。氯沙坦治疗可显著改善SHR缺血再灌注期间的内皮依赖性舒张和心脏功能。外源性ADMA也加重了WKY离体灌注心脏缺血再灌注诱导的心肌损伤,表现为肌酸激酶释放增加和心脏功能降低。目前的结果表明,氯沙坦对缺血再灌注诱导的心肌损伤的保护作用与ADMA水平降低有关。